Dr. Orellana-Noia on the Treatment of High-Risk and Vulnerable Patient Populations with DLBCL

In Partnership With:

Victor M. Orellana-Noia, MD, discusses the treatment of high-risk and vulnerable patients with diffuse large B-cell lymphoma.

Victor M. Orellana-Noia, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, discusses the treatment of high-risk and vulnerable patients with diffuse large B-cell lymphoma (DLBCL).

Although there are data emerging from many phase 2 and 3 trials in DLBCL and other hematologic malignancies, high-risk and vulnerable patient populations are often excluded from these trials, Orellana-Noia adds. The younger, more fit patients enrolled in these trials generally do not present with central nervous system disease, HIV, prior solid organ transplant, and more, Orellana-Noia explains.

Investigators must make efforts to make clinical trial eligibility more inclusive to evaluate emerging therapies in patients who have higher-risk disease, Orellana-Noia concludes.

Related Videos
View All
Related Content